Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

SHSE:688621 Stock Report

Market Cap: CN¥4.5b

Beijing Sun-Novo Pharmaceutical Research Management

Management criteria checks 3/4

Beijing Sun-Novo Pharmaceutical Research's CEO is Yujing Liu, appointed in Mar 2020, has a tenure of 4.75 years. directly owns 4.06% of the company’s shares, worth CN¥183.33M. The average tenure of the management team and the board of directors is 5.3 years and 4.8 years respectively.

Key information

Yujing Liu

Chief executive officer

CN¥2.3m

Total compensation

CEO salary percentagen/a
CEO tenure4.8yrs
CEO ownership4.1%
Management average tenure5.3yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

Investors Still Aren't Entirely Convinced By Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (SHSE:688621) Earnings Despite 40% Price Jump

Oct 02
Investors Still Aren't Entirely Convinced By Beijing Sun-Novo Pharmaceutical Research Co., Ltd.'s (SHSE:688621) Earnings Despite 40% Price Jump

Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance

Sep 05
Concerns Surrounding Beijing Sun-Novo Pharmaceutical Research's (SHSE:688621) Performance

Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)

Jul 31
Market Still Lacking Some Conviction On Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHSE:688621)

We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt

May 29
We Think Beijing Sun-Novo Pharmaceutical Research (SHSE:688621) Can Stay On Top Of Its Debt

CEO

Yujing Liu (42 yo)

4.8yrs

Tenure

CN¥2,250,100

Compensation

Mr. Yujing Liu serves as Director and General Manager at Beijing Sun-Novo Pharmaceutical Research Co.,Ltd. since March 2020.


Leadership Team

NamePositionTenureCompensationOwnership
Yujing Liu
GM & Director4.8yrsCN¥2.25m4.06%
CN¥ 183.3m
Lingyang Zhao
CFO, Board Secretaryno dataCN¥1.04m0.54%
CN¥ 24.3m
Yan Shao
Deputy General Manager4.8yrsCN¥1.16m2.25%
CN¥ 101.5m
Guangtao Hao
Deputy GM & Core Technician4.8yrsCN¥1.11mno data
Huan Luo
Deputy GM & Core Technician4.8yrsCN¥1.32mno data
Yuanbo Li
Deputy General Manager6.7yrsCN¥938.21kno data
Wang Mingjuan
Core Technical Staff5.8yrsCN¥452.10kno data
Xie Daosheng
Core Technical Staff7.5yrsCN¥917.00kno data
Gao Jian
Core Technical Staff6.6yrsCN¥355.30kno data

5.3yrs

Average Tenure

43yo

Average Age

Experienced Management: 688621's management team is seasoned and experienced (5.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Yujing Liu
GM & Director4.8yrsCN¥2.25m4.06%
CN¥ 183.3m
Lingyang Zhao
CFO, Board Secretary4.8yrsCN¥1.04m0.54%
CN¥ 24.3m
Qiao Chen
Director4.8yrsno datano data
Zhuangkun He
Independent Director4.8yrsCN¥120.00kno data
Ying Zhang
Director4.8yrsno datano data
Chen Li
Chairman of the Board4.8yrsCN¥1.50m27.59%
CN¥ 1.2b
Wenran Li
Director4.8yrsno datano data
Dandan Wang
Chairman of the Supervisory Board4.8yrsno datano data
Jinfeng Zhang
Employee Representative Supervisor4.8yrsno datano data

4.8yrs

Average Tenure

42yo

Average Age

Experienced Board: 688621's board of directors are considered experienced (4.8 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 01:34
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yinglan ShuHaitong International Research Limited
Hanyang HuangIndustrial Securities Co. Ltd.
Jiaqi ZhuZhongtai Securities Co. Ltd.